Germany's Boehringer Ingelheim is entering into a strategic alliance with Shanghai-based Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) to construct a cGMP biopharmaceuticals facility in China.Scheduled to commence operations in early 2016, the new facility will be the first to use mammalian cell culture technology in the production of biopharmaceuticals in China. The new facility will offer a range of development and clinical services set to carry out technical process development and cGMP manufacturing. Read the full story.